

DOCKET NO.: C1039.70074US00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Krieg et al. Serial No.: 10/679,710

Confirmation No.:

9983

Filed:

October 3, 2003

For:

IMMUNOSTIMULATORY NUCLEIC ACID

**MOLECULES** 

Examiner:

M. S. Horning

Art Unit:

1648

## **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 13th day of August, 2007.

Sheila Gravina

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

08/16/2007 HDESTA1 00000029 10679710

02 FC:1806

180.00 OP

Conf. No.: 9983

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants also call to the attention of the Examiner the following co-pending patent applications and Office Actions cited therein. Copies of the Office Actions are enclosed.

Office Actions (copies enclosed)				
Serial No.	Date Mailed from			
	PTO			
09/337,619	10/03/2000			
09/337,619	02/26/2002			
10/719,493	09/01/2005			
10/719,493	07/19/2006			
10/719,493	02/07/2007			

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Serial No.: 10/679,710 - 3 -Art Unit: 1648

Conf. No.: 9983

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 23/2825, under Docket No.C1039.70074US00.

Respectfully submitted,

By:

Patrick R.H. Waller, Ph.D., Reg. No. 41,418 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

x08/13/07x

Docket No.: C1039.70074US00

Date: August 13, 2007

OIP E								
FORM PTO-1449 and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICA	APPLICATION NO.: 10/679,710 ATTY. DOC		CKET NO.: C1039.70074US00		
			FILING I	FILING DATE: October 3, 2003		CONFIRMATION NO.: 9983		
			APPLICANT: Krieg et al.					
Sheet	1	of	1	GROUP	ART UNIT: 1648	EXAMINER	: M. S. H	Iorning
				<b>U.S.</b> 1	PATENT DOCUMENTS			
Examiner's Initials #	Cite	U.S	S. Patent Docum	Name of Patentee or Applica		nt of Lited L		cation or Issue
	No.	Nι	ımber	Kind Code	I Document I		MM-DD-Y	
			_					
<u>_</u>								
				FOREIC	EN PATENT DOCUMENTS			
Examiner's	Cite	Foreign Patent Documen			Name of Patentee or Applica	ant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Cited Do	Cited Document MM-DD-YYYY	ent (Y/N)	
	-							
	<u> </u>							<del></del>
<del></del>	<del> </del>							
					PATENT LITERATURE DOCU			
Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item  (book magazine journal serial symposium catalog etc.) date page(s) volume issue number(s) publisher.  Translation				Translation (Y/N)		
		Clinical Tr	rmaceutical Gr rials for PF-35	2676 Com	y Pharmaceutical Group Annour bined with Cytotoxic Chemothe	nces Pfizer's D rapy in Advan	iscontinuation of ced Non Small	

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Coley Pharmaceutical Group, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer," Press Release (June 20, 2007)	

EXAMINER:	DATE CONSIDERED:		

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).